Teva Pharma (TEVA) Reports In-Line Q2 EPS; Lowers Revenue Outlook
Get Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharma (NYSE: TEVA) reported Q2 EPS of $0.59, in-line with the analyst estimate of $0.59. Revenue for the quarter came in at $3.9 billion versus the consensus estimate of $4.04 billion.
GUIDANCE:
Teva Pharma sees FY2021 EPS of $2.50-$2.70, versus the consensus of $2.45. Teva Pharma sees FY2021 revenue of $16-16.4 billion, versus prior of $16.4-$16.8 billion and the consensus of $16.55 billion.
For earnings history and earnings-related data on Teva Pharma (TEVA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- Veralto Corporation (VLTO) Tops Q1 EPS by 6c, Offers Guidance
- Baker Hughes Company (BKR) Tops Q1 EPS by 4c, Beats on Revenue
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!